Press "Enter" to skip to content

Analysis of Colorectal Cancer Diagnostics and Therapeutics Market 2019-2024: Industry Trends, Share, Size, Price, Revenue, Business Strategy, Production Technology Forecast to 2024

Colorectal

The “Colorectal Cancer Diagnostics and Therapeutics Market” research report 2019-2024 delivers comprehensive information and valuable insights about the Colorectal Cancer Diagnostics and Therapeutics industry. The information available in the Colorectal Cancer Diagnostics and Therapeutics market report is not only based on the facts but also on the case studies, which analysts have included to convey appropriate information to the clients in a well-versed manner. Colorectal Cancer Diagnostics and Therapeutics market report includes valuable information to assist new entrants, as well as established players, to understand the prevailing trends in the market.

Some Companies Are Covered in the Colorectal Cancer Diagnostics and Therapeutics Market:

  • Abbott Laboratories
  • Amgen Inc.
  • Clinical Genomics
  • EDP Biotech
  • Epigenomics AG
  • F. Hoffmann
  • La Roche AG
  • Novigenix SA
  • Quest Diagnostics
  • Sanofi SA
  • Siemens Healthineers
  • VolitionRX

    Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/14245285

    Market Overview:

  • The colorectal cancer diagnostics and therapeutics market are expected to register a CAGR of nearly 4.6% during the forecast period, 2019-2024.
  • – Colorectal cancer has one of the largest incidence and prevalence rates, worldwide. Primary causes of colorectal cancer are said to be lifestyle disorders, ageing, and diet.
  • – According to the World Health Organization (WHO), an increase of around 70% is expected in the colorectal cancer cases across the world, by 2030.
  • – Therefore, high incidence and prevalence rates are the primary factors, driving the market studied.
  • – According to a research article published in 2016, “Colorectal cancer is a leading cause of cancer incidence and mortality among adults younger than 50 years in the United States”.
  • – Colorectal cancer (CRC) is estimated to account for over 9% of all cancer incidences and is a major cause of morbidity and mortality throughout the world. CRC is the second-most-common cause of cancer-related deaths in the United States.<

    Scope of the Report:

  • Colorectal cancer, also known as bowel cancer, colon cancer, or rectal cancer, and is any form of cancer that affects the colon and the rectum. The report tracks revenue generated by therapeutics used for the management of colorectal cancer, along with various screening tests, kits, and medical devices used for the diagnosis of colorectal cancer.

    Reasons for Buying Colorectal Cancer Diagnostics and Therapeutics Market Report:

    • This report provides pin-point analysis for changing competitive dynamics
    • It provides a forward looking perspective on different factors driving or restraining market growth
    • It provides a five-year forecast assessed on the basis of how the market is predicted to grow
    • It helps in understanding the key product segments and their future
    • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
    • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

    For More Information or Query or Customization Before Buying, Visit at – https://www.industryresearch.co/enquiry/pre-order-enquiry/14245285

    Key Market Trends:

    Immunotherapy Blockbusters to Remain a Significant Revenue Source For Leading Players Due to Label Expansions Despite Approaching Patent Expiry.

    Bevacizumab (Avastin) is a monoclonal antibody that prevents tumors from growing in blood vessels, by antagonizing vascular endothelial growth factor (VEGF), which is a substance released by tumors to stimulate new blood vessel formation. The FDA approved a labeling extension for bevacizumab, administered in combination with intravenous 5-fluorouracil-based chemotherapy, for the second-line treatment of metastatic carcinoma of the colon or rectum. The approval of cyramza (ramucirumab) for second-line Avastin pre-treated metastatic setting, in 2016, is expected to propel the growth of the colorectal cancer drugs market, in the future.

    The United States is Expected to Retain Largest Market Share During the Forecast Period

    Geographically, the United States holds the largest market share with respect to demand and revenue. In 2017, 39,910 new rectal cancer cases and 95,520 new colon cancer cases were reported in the United States based on the estimates by the American Cancer Society. These estimates indicate that colorectal cancer is increasing its prevalence in the United States, which is in turn, leading to the growth of the market. The Asia-Pacific is also expected to witness a strong growth pattern in the coming years, with China and India showing rapid progress. In 2015, Roche signed an agreement with an insurance company in Shenzhen City. The Chinese people were among the first few to approve Avastin for reimbursement. This is expected to increase access to colorectal cancer therapeutics in China.

    Colorectal Cancer Diagnostics and Therapeutics Market Report Provides Comprehensive Analysis of:

    • Functional market industry outline
    • Up and downstream industry examination
    • Channels and propositions believability
    • Market challenge by key players
    • Enhancement suggestions examination

    Purchase this Report (Price 4250 USD for single user license) – https://www.industryresearch.co/purchase/14245285

    Report Highlights:

    • Market Dynamics – Drivers, Restraints, and Opportunities
    • Market Segmentation – Types, Applications, Regions, and Technology
    • Market Trends
    • Competitive Landscape
    • SWOT Analysis and Porter’s Five Forces Analysis

    Detailed TOC of Colorectal Cancer Diagnostics and Therapeutics Market Report 2019-2024:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Market Drivers
    4.2.1 Technological Advancements in Radiology and Chemotherapy
    4.2.2 Increasing Incidence and Prevalence of Colorectal Cancer
    4.3 Market Restraints
    4.3.1 High Costs Associated with Drugs
    4.3.2 Side Effects Associated With Drugs
    4.4 Porter’s Five Force Analysis
    4.4.1 Threat of New Entrants
    4.4.2 Bargaining Power of Buyers/Consumers
    4.4.3 Bargaining Power of Suppliers
    4.4.4 Threat of Substitute Products
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 By Modality
    5.1.1 Diagnostics Techniques
    5.1.1.1 Stool Tests
    5.1.1.2 Immunohistochemistry
    5.1.1.3 Colonoscopy
    5.1.1.4 Flexible Sigmoidoscopy
    5.1.1.5 Other Diagnostics Techniques
    5.1.2 Therapeutics
    5.1.2.1 Chemotherapy
    5.1.2.1.1 Antimetabolites
    5.1.2.1.1.1 Fluorouracil
    5.1.2.1.1.2 Capecitabine
    5.1.2.1.2 Alkylating Agent
    5.1.2.1.2.1 Oxaliplatin
    5.1.2.1.3 Other Chemotherapeutic Agents
    5.1.2.2 Immunotherapy
    5.1.2.2.1 Bevacizumab
    5.1.2.2.2 Cetuximab
    5.1.2.2.3 Panitumumab
    5.1.2.3 Chemoprotectant
    5.1.2.4 Others
    5.2 Geography
    5.2.1 North America
    5.2.1.1 United States
    5.2.1.2 Canada
    5.2.1.3 Mexico
    5.2.2 Europe
    5.2.2.1 Germany
    5.2.2.2 United Kingdom
    5.2.2.3 France
    5.2.2.4 Italy
    5.2.2.5 Spain
    5.2.2.6 Rest of Europe
    5.2.3 Asia-Pacific
    5.2.3.1 China
    5.2.3.2 Japan
    5.2.3.3 India
    5.2.3.4 Australia
    5.2.3.5 South Korea
    5.2.3.6 Rest of Asia-Pacific
    5.2.4 Middle East & Africa
    5.2.4.1 GCC
    5.2.4.2 South Africa
    5.2.4.3 Rest of Middle East & Africa
    5.2.5 South America
    5.2.5.1 Brazil
    5.2.5.2 Argentina
    5.2.5.3 Rest of South America

    6 COMPETITIVE LANDSCAPE
    6.1 Company Profiles
    6.1.1 Abbott Laboratories
    6.1.2 Amgen Inc.
    6.1.3 Clinical Genomics
    6.1.4 EDP Biotech
    6.1.5 Epigenomics AG
    6.1.6 F. Hoffmann-La Roche AG
    6.1.7 Novigenix SA
    6.1.8 Quest Diagnostics
    6.1.9 Sanofi SA
    6.1.10 Siemens Healthineers
    6.1.11 VolitionRX

    7 MARKET OPPORTUNITIES AND FUTURE TRENDS

     

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Paint Market 2019 Offers Newest Industry Data, Industry Future Trends, Sales, Revenue, Growth Rate by Types and Applications Forecast till 2023

    Global Neckband Headphones Market 2019 by Price Analysis, Supply Chain Analysis, Production, Consumption, Supplier, Cost Structure Market Analysis Forecast to 2023

    CD Player Market 2019 Size, Global Trends, Comprehensive Research Study, Development Status, Opportunities, Future Plans, Competitive Landscape and Growth by Forecast 2025

    Global Tailpipe Market 2019 by Major Companies, Regional Analysis, Recent Development, Future Prospects Forecast to 2024

  • Be First to Comment

    Leave a Reply

    Your email address will not be published. Required fields are marked *